414 results on '"Relling, M V"'
Search Results
2. A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment
3. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy
4. Pharmacodynamics in Childhood Acute Lymphoblastic Leukemia
5. Infection-related complications during treatment for childhood acute lymphoblastic leukemia
6. A revised definition for cure of childhood acute lymphoblastic leukemia
7. Risk-Adapted Treatment for Acute Lymphoblastic Leukemia: Findings from St. Jude Children’s Research Hospital
8. Current Treatment and Results of St. Jude Studies for Childhood Acute Lymphoblastic Leukemia
9. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase
10. Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression
11. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia
12. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy
13. A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity
14. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia
15. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype
16. Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL)
17. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1
18. Genome scan implicates adhesion biological pathways in secondary leukemia
19. Genome-wide approach to identify risk factors for therapy-related myeloid leukemia
20. Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation
21. Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse
22. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia
23. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients
24. The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced Ototoxicity in Children With Cancer
25. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation
26. Clinical Implementation of Pharmacogenetics: More Than One Gene at a Time
27. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update
28. A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record
29. Pharmacogenomics and Individualized Medicine: Translating Science Into Practice
30. Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods
31. ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence
32. Functional Characterization of Liver Enhancers That Regulate Drug-Associated Transporters
33. CPIC:Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
34. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
35. Promoter Polymorphisms in the β-2 Adrenergic Receptor Are Associated With Drug-Induced Gene Expression Changes and Response in Acute Lymphoblastic Leukemia
36. Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity
37. Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia
38. Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia
39. Etoposide Sensitivity Does Not Predict MLL Rearrangements or Risk of Therapy-Related Acute Myeloid Leukemia
40. Using HapMap Tools in Pharmacogenomic Discovery: The Thiopurine Methyltransferase Polymorphism
41. Should Pharmacogenomic Studies be Required for New Drug Approval?
42. The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
43. MLL methylation is not likely a common mechanism for therapy-related AML
44. Risk-Adapted Treatment for Acute Lymphoblastic Leukemia: Findings from St. Jude Children’s Research Hospital
45. HIGH VARIABILITY IN SN-38 GLUCURONIDATION IN LIVER SAMPLES FROM AFRICAN POPULATION AS PREDICTED BY UGT1A1 GENOTYPES
46. CYP1A2 4-HYDROXYLATES PROPRANOLOL
47. CYTOCHROME P450 IN NORMAL PEDIATRIC VS ADULT HUMAN LIVER
48. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
49. The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia
50. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.